Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
1.
Oncogene ; 29(33): 4715-24, 2010 Aug 19.
Article in English | MEDLINE | ID: mdl-20562907

ABSTRACT

The TP53 tumor suppressor gene is the most commonly mutated gene in human cancers. To evaluate the biological and clinical relevance of p53 loss, human somatic cell gene targeting was used to delete the TP53 gene in the non-tumorigenic epithelial cell line, MCF-10A. In all four p53-/- clones generated, cells acquired the capability for epidermal growth factor-independent growth and were defective in appropriate downstream signaling and cell cycle checkpoints in response to DNA damage. Interestingly, p53 loss induced chromosomal instability leading to features of transformation and the selection of clones with varying phenotypes. For example, p53-deficient clones were heterogeneous in their capacity for anchorage-independent growth and invasion. In addition, and of clinical importance, the cohort of p53-null clones showed sensitivity to chemotherapeutic interventions that varied depending not only on the type of chemotherapeutic agent, but also on the treatment schedule. In conclusion, deletion of the TP53 gene from MCF-10A cells eliminated p53 functions, as well as produced p53-/- clones with varying phenotypes possibly stemming from the distinct chromosomal changes observed. Such a model system will be useful to further understand the cancer-specific phenotypic changes that accompany p53 loss, as well as help to provide future treatment strategies for human malignancies that harbor aberrant p53.


Subject(s)
Breast Neoplasms/genetics , Breast/physiology , Cell Transformation, Neoplastic/genetics , Genes, p53 , Mammary Glands, Human/metabolism , Animals , Breast/metabolism , Breast/pathology , Breast Neoplasms/drug therapy , Breast Neoplasms/metabolism , Breast Neoplasms/pathology , Cell Growth Processes/physiology , Cell Line , Cell Transformation, Neoplastic/metabolism , Cell Transformation, Neoplastic/pathology , Chromosomal Instability , Doxorubicin/pharmacology , Epithelial Cells/metabolism , Epithelial Cells/pathology , Female , Gene Knockout Techniques , Humans , Mammary Glands, Human/pathology , Mice , Mice, Nude
2.
Cancer Gene Ther ; 14(1): 98-104, 2007 Jan.
Article in English | MEDLINE | ID: mdl-17082796

ABSTRACT

The use of gene therapy to correct mutated or lost gene function for the treatment of human cancers has been an active, yet problematic area of biomedical research. Many technical difficulties, including efficient tissue-specific delivery, integration site specificity and general toxicity, are being addressed. Little is known, however, about the genetic and phenotypic stability that accompanies a successful gene-specific targeting event in a cancer cell. This question was addressed following the creation of a colon cancer cell line in which a mutated hMLH1 gene was corrected via targeted homologous recombination. This correction resulted in the expression of wild-type hMLH1 protein, restoration of the hPMS2 protein and mismatch repair (MMR) proficiency. One of two hMLH1-corrected clones, however, was found to retain defects in MMR activity. These cells continued to express the corrected hMLH1 protein, but had lost expression of another MMR protein, hMSH6. DNA sequence analysis of the hMSH6 gene revealed biallelic expansions of a cytosine repeat region in exon 5 that result in frameshifts leading to premature stop codons. These findings suggest that, similar to acquired drug resistance, the presence of genetically heterogeneous cancer cell populations or acquisition of compensatory mutations can result in 'resistance' to gene replacement therapy.


Subject(s)
Base Pair Mismatch , Carrier Proteins/genetics , DNA Repair , Nuclear Proteins/genetics , Adaptor Proteins, Signal Transducing , Base Sequence , Blotting, Western , Cell Line, Tumor , DNA Primers , Humans , MutL Protein Homolog 1
3.
Oncogene ; 25(40): 5561-9, 2006 Sep 07.
Article in English | MEDLINE | ID: mdl-16619041

ABSTRACT

Transforming growth factor-beta type 1 (TGF-beta) has been implicated as both a tumor suppressor and a tumor promoter in many solid epithelial cancers. We have previously demonstrated that the cyclin dependent kinase (CDK) inhibitor p21 acts as a molecular switch in determining a growth inhibitory versus growth proliferative response to TGF-beta in the spontaneously immortalized human mammary epithelial cell line MCF-10A. We now demonstrate that this proliferative effect of TGF-beta is mediated through the proinflammatory cytokine, interleukin-1alpha (IL-1alpha). Using gene expression array analysis, we identified IL-1alpha as a cytokine specifically upregulated only in cells lacking p21 and only upon TGF-beta stimulation. Cell proliferation assays verified that recombinant IL-1alpha was capable of inducing a growth proliferative response in p21 null MCF-10A cells, while neutralizing antibodies against IL-1alpha prevented the growth proliferative effects of TGF-beta. Mechanistically, both the CDK and proliferating cell nuclear antigen (PCNA) inhibitory functions of p21 were responsible for preventing TGF-beta induced cell proliferation, but only PCNA inhibition by p21 regulated IL-1alpha gene expression. These studies demonstrate a novel role for IL-1alpha in mediating a proliferative response to TGF-beta signaling, and suggest that therapies directed against IL-1alpha could abate the growth proliferative effects of TGF-beta without compromising its tumor suppressive function.


Subject(s)
Cyclin-Dependent Kinase Inhibitor p21/genetics , Interleukin-1/metabolism , Second Messenger Systems , Transforming Growth Factor beta/metabolism , Cell Line, Tumor , Cell Proliferation , Cyclin-Dependent Kinase Inhibitor p21/metabolism , Dactinomycin/pharmacology , Humans , Interleukin-1/genetics , Nucleic Acid Synthesis Inhibitors/pharmacology , Oligonucleotide Array Sequence Analysis , Proliferating Cell Nuclear Antigen/metabolism , Reverse Transcriptase Polymerase Chain Reaction , Signal Transduction , Up-Regulation
4.
Br J Cancer ; 94(4): 455-9, 2006 Feb 27.
Article in English | MEDLINE | ID: mdl-16449998

ABSTRACT

It is now well established that cancer is a genetic disease and that somatic mutations of oncogenes and tumour suppressor genes are the initiators of the carcinogenic process. The phosphatidylinositol 3-kinase signalling pathway has previously been implicated in tumorigenesis, and evidence over the past year suggests a pivotal role for the phosphatidylinositol 3-kinase catalytic subunit, PIK3CA, in human cancers. In this review, we analyse recent reports describing PIK3CA mutations in a variety of human malignancies, and discuss their possible implications for diagnosis and therapy.


Subject(s)
Mutation , Neoplasms/genetics , Phosphatidylinositol 3-Kinases/metabolism , Class I Phosphatidylinositol 3-Kinases , Humans , Neoplasms/diagnosis , Neoplasms/therapy , Phosphatidylinositol 3-Kinases/genetics , Signal Transduction
5.
Oncogene ; 20(24): 3156-65, 2001 May 28.
Article in English | MEDLINE | ID: mdl-11420732

ABSTRACT

Cancer is a process driven by the accumulation of abnormalities in gene function. While many of these changes are genetic, epigenetically mediated changes in gene expression are being increasingly appreciated. This latter process emphasizes the need to understand two key components of heritable, but reversible, modulation of gene promoter function that are closely tied to one another - formation of chromatin which modulates transcription and establishing patterns of DNA methylation. The link lies first in the recruitment to methylated cytosines of a family of methyl-CpG binding domain proteins (MBDs), which are direct transcriptional repressors and can complex with transcriptional corepressors including histone deacetylases (HDACs). Additionally, the proteins that catalyze DNA methylation, DNA methyltransferases (DNMTs), also directly repress transcription and associate with HDACs. Regulation of these above chromatin-DNA methylation interactions as a function of DNA replication timing is emerging as a key event in the inheritance of transcriptionally repressed domains of the genome. Importantly, synergy between HDAC activity and DNA methylation is operative for a key epigenetic abnormality in cancer cells, transcriptional silencing of tumor suppressor genes. This change has now been recognized for genes that are essential for normal regulation of virtually every major cell function including cell growth, differentiation, apoptosis, DNA repair, and cell-cell, cell-substratum interaction. Understanding the molecular determinants of both normal and abnormal patterns of chromatin formation and DNA methylation thus holds great promise for our understanding of cancer and for means to better diagnose, prevent, and treat this disease.


Subject(s)
Chromatin/genetics , DNA Methylation , Neoplasms/genetics , Animals , Chromatin/metabolism , DNA, Neoplasm/genetics , DNA, Neoplasm/metabolism , Gene Expression Regulation, Neoplastic , Humans , Neoplasms/metabolism , Neoplasms/pathology , Transcription, Genetic
6.
J Biol Chem ; 276(34): 32282-7, 2001 Aug 24.
Article in English | MEDLINE | ID: mdl-11427539

ABSTRACT

We demonstrate that the recently identified DNA methyltransferases, Dnmt3a and Dnmt3b, like DNMT1, repress transcription in a methylation-independent manner. Dnmt3a and Dnmt3b repress transcription primarily through a plant homeodomain-like motif that is shared with the ATRX protein but is not present in DNMT1. Unlike DNMT1, which localizes to replication foci during S-phase in murine embryonic fibroblasts, Dnmt3a co-localizes with heterochromatin protein 1 alpha (HP1 alpha) and methyl-CpG binding proteins throughout the cell cycle to late-replicating pericentromeric heterochromatin. In contrast to Dnmt3a, Dnmt3b remained diffuse in the nucleus of embryonic fibroblasts at all cell cycle stages. However, Dnmt3a and Dnmt3b co-localize to these pericentromeric heterochromatin regions in murine embryonic stem cells. This finding is important to the fact that mutations in DNMT3B are found in the developmental syndrome, ICF (immunodeficiency, centromeric heterochromatin instability, and facial anomalies), which involves extensive loss of methylation from pericentromeric regions. The localization of Dnmt3a and Dnmt3b was unaffected in Dnmt1 null embryonic stem cells, which lose the majority of methylation at pericentromeric major satellite repeats, suggesting that these enzymes are not dependent upon preexisting methylation for their targeting. DNMT1 is then positioned to reestablish transcriptionally repressive chromatin as cells replicate, while Dnmt3a and Dnmt3b may help to establish such chromatin in late S-phase and maintain this repressive heterochromatin throughout the cell cycle in a developmentally and/or cell type manner.


Subject(s)
DNA (Cytosine-5-)-Methyltransferases/metabolism , DNA Helicases , Heterochromatin/metabolism , Nuclear Proteins , Repressor Proteins/metabolism , Transcription, Genetic , 3T3 Cells , Animals , DNA (Cytosine-5-)-Methyltransferases/chemistry , DNA Methyltransferase 3A , DNA-Binding Proteins/metabolism , Histone Deacetylases/metabolism , Mice , Repressor Proteins/chemistry , Transcription Factors/metabolism , X-linked Nuclear Protein , DNA Methyltransferase 3B
7.
Hum Mol Genet ; 10(7): 687-92, 2001 Apr.
Article in English | MEDLINE | ID: mdl-11257100

ABSTRACT

Gene function in cancer can be disrupted either through genetic alterations, which directly mutate or delete genes, or epigenetic alterations, which alter the heritable state of gene expression. The latter events are mediated by formation of transcriptionally repressive chromatin states around gene transcription start sites and an associated gain of methylation in normally unmethylated CpG islands in these regions. The genes affected include over half of the tumor suppressor genes that cause familial cancers when mutated in the germline; the selective advantage for genetic and epigenetic dysfunction in these genes is very similar. The aberrant methylation can begin very early in tumor progression and mediate most of the important pathway abnormalities in cancer including loss of cell cycle control, altered function of transcription factors, altered receptor function, disruption of normal cell-cell and cell-substratum interaction, inactivation of signal transduction pathways, loss of apoptotic signals and genetic instability. The active role of the aberrant methylation in transcriptional silencing of genes is becoming increasingly understood and involves a synergy between the methylation and histone deacetylase (HDAC) activity. This synergy can be mediated directly by HDAC interaction with DNA methylating enzymes and by recruitment through complexes involving methyl-cytosine binding proteins. In the translational arena, the promoter hypermethylation changes hold great promise as DNA tumor markers and their potentially reversible state creates a target for cancer therapeutic strategies involving gene reactivation.


Subject(s)
Chromatin/physiology , DNA Methylation , Gene Expression Regulation, Neoplastic , Neoplasms/genetics , Neoplasms/metabolism , Animals , Chromatin/metabolism , CpG Islands , Disease Progression , Gene Silencing , Humans , Models, Biological , Mutation , Promoter Regions, Genetic , Transcription, Genetic
8.
FEBS Lett ; 476(3): 203-7, 2000 Jul 07.
Article in English | MEDLINE | ID: mdl-10913614

ABSTRACT

Gut-enriched Krüppel-like factor (GKLF) is a zinc finger-containing transcription factor, the expression of which is associated with growth arrest. We compared Gklf expression in intestinal and colonic adenomas to normal mucosa in multiple intestinal neoplasia (Min) mice and familial adenomatous polyposis (FAP) patients, respectively, using semi-quantitative RT-PCR. In Min mice, the level of Gklf transcript is highest in normal-appearing intestinal tissues and decreases as the size of the adenoma increases. In FAP patients, the level of GKLF transcript is lower in adenomas compared to paired normal-appearing mucosa from the same patient or normal colonic mucosa from control individuals without FAP. The possibility of DNA methylation as a cause for the decreased expression of Gklf in adenomas of Min mice was investigated by methylation-specific PCR. Results indicate that the Gklf gene is not methylated in either normal or tumorous tissues. The findings of our study are therefore consistent with the potential role of GKLF as a negative growth regulator of gut epithelial cells.


Subject(s)
Adenoma/genetics , Adenomatous Polyposis Coli/genetics , DNA-Binding Proteins , Growth Inhibitors/genetics , Intestinal Neoplasms/genetics , Transcription Factors/genetics , Animals , Base Sequence , Case-Control Studies , DNA Methylation , DNA Primers/genetics , DNA, Neoplasm/chemistry , DNA, Neoplasm/genetics , Down-Regulation , Female , Humans , Kruppel-Like Factor 4 , Kruppel-Like Transcription Factors , Male , Mice , Mice, Inbred C57BL , Mice, Mutant Strains , Polymerase Chain Reaction , Zinc Fingers/genetics
9.
Nat Genet ; 25(3): 269-77, 2000 Jul.
Article in English | MEDLINE | ID: mdl-10888872

ABSTRACT

DNA methylation can contribute to transcriptional silencing through several transcriptionally repressive complexes, which include methyl-CpG binding domain proteins (MBDs) and histone deacetylases (HDACs). We show here that the chief enzyme that maintains mammalian DNA methylation, DNMT1, can also establish a repressive transcription complex. The non-catalytic amino terminus of DNMT1 binds to HDAC2 and a new protein, DMAP1 (for DNMT1 associated protein), and can mediate transcriptional repression. DMAP1 has intrinsic transcription repressive activity, and binds to the transcriptional co-repressor TSG101. DMAP1 is targeted to replication foci through interaction with the far N terminus of DNMT1 throughout S phase, whereas HDAC2 joins DNMT1 and DMAP1 only during late S phase, providing a platform for how histones may become deacetylated in heterochromatin following replication. Thus, DNMT1 not only maintains DNA methylation, but also may directly target, in a heritable manner, transcriptionally repressive chromatin to the genome during DNA replication.


Subject(s)
DNA (Cytosine-5-)-Methyltransferases/metabolism , DNA Replication , Histone Deacetylases/metabolism , Repressor Proteins/metabolism , Transcription, Genetic , Amino Acid Sequence , Animals , Base Sequence , COS Cells , Chlorocebus aethiops , DNA (Cytosine-5-)-Methyltransferase 1 , DNA (Cytosine-5-)-Methyltransferases/genetics , DNA, Complementary , DNA-Binding Proteins/genetics , DNA-Binding Proteins/metabolism , Endosomal Sorting Complexes Required for Transport , Gene Expression Regulation , Genes, Reporter , Histone Deacetylase 2 , Humans , Hydro-Lyases/genetics , Mice , Molecular Sequence Data , Repressor Proteins/genetics , S Phase , Transcription Factors/genetics , Transcription Factors/metabolism , Vero Cells
10.
Cancer Res ; 59(4): 798-802, 1999 Feb 15.
Article in English | MEDLINE | ID: mdl-10029065

ABSTRACT

Tissue inhibitor of metalloproteinase-3 (TIMP-3) antagonizes matrix metalloproteinase activity and can suppress tumor growth, angiogenesis, invasion, and metastasis. Loss of TIMP-3 has been related to the acquisition of tumorigenesis. Herein, we show that TIMP-3 is silenced in association with aberrant promoter-region methylation in cell lines derived from human cancers. TIMP-3 expression was restored after 5-aza-2'deoxycytidine-mediated demethylation of the TIMP-3 proximal promoter region. Genomic bisulfite sequencing revealed that TIMP-3 silencing was related to the overall density of methylation and that discrete regions within the TIMP-3 CpG island may be important for the silencing of this gene. Aberrant methylation of TIMP-3 occurred in primary cancers of the kidney, brain, colon, breast, and lung, but not in any of 41 normal tissue samples. The most frequent TIMP-3 methylation was found in renal cancers, which originate in the tissue that normally expresses the highest TIMP-3 levels. This methylation correlated with a lack of detectable TIMP-3 protein in these tumors. Together, these data show that methylation-associated inactivation of TIMP-3 is frequent in many human tumors.


Subject(s)
Brain Neoplasms/genetics , DNA Methylation , Kidney Neoplasms/genetics , Tissue Inhibitor of Metalloproteinase-3/genetics , Azacitidine/analogs & derivatives , Azacitidine/pharmacology , CpG Islands , Decitabine , Humans
11.
Nat Genet ; 21(1): 103-7, 1999 Jan.
Article in English | MEDLINE | ID: mdl-9916800

ABSTRACT

Densely methylated DNA associates with transcriptionally repressive chromatin characterized by the presence of underacetylated histones. Recently, these two epigenetic processes have been dynamically linked. The methyl-CpG-binding protein MeCP2 appears to reside in a complex with histone deacetylase activity. MeCP2 can mediate formation of transcriptionally repressive chromatin on methylated promoter templates in vitro, and this process can be reversed by trichostatin A (TSA), a specific inhibitor of histone deacetylase. Little is known, however, about the relative roles of methylation and histone deacetylase activity in the stable inhibition of transcription on densely methylated endogenous promoters, such as those for silenced alleles of imprinted genes, genes on the female inactive X chromosome and tumour-suppressor genes inactivated in cancer cells. We show here that the hypermethylated genes MLH1, TIMP3 (TIMP3), CDKN2B (INK4B, p15) and CDKN2A (INK4, p16) cannot be transcriptionally reactivated with TSA alone in tumour cells in which we have shown that TSA alone can upregulate the expression of non-methylated genes. Following minimal demethylation and slight gene reactivation in the presence of low dose 5-aza-2'deoxycytidine (5Aza-dC), however, TSA treatment results in robust re-expression of each gene. TSA does not contribute to demethylation of the genes, and none of the treatments alter the chromatin structure associated with the hypermethylated promoters. Thus, although DNA methylation and histone deacetylation appear to act as synergistic layers for the silencing of genes in cancer, dense CpG island methylation is dominant for the stable maintenance of a silent state at these loci.


Subject(s)
Cell Cycle Proteins , DNA Methylation , Gene Expression Regulation, Neoplastic/drug effects , Histone Deacetylase Inhibitors , Hydroxamic Acids/pharmacology , Tumor Suppressor Proteins , Adaptor Proteins, Signal Transducing , Azacitidine/analogs & derivatives , Azacitidine/pharmacology , Carrier Proteins/genetics , CpG Islands , Cyclin-Dependent Kinase Inhibitor p15 , Cyclin-Dependent Kinase Inhibitor p16/genetics , DNA Modification Methylases/antagonists & inhibitors , Decitabine , Enzyme Inhibitors/pharmacology , Humans , MutL Protein Homolog 1 , Neoplasm Proteins/genetics , Neoplasms/genetics , Nuclear Proteins , Promoter Regions, Genetic , Tissue Inhibitor of Metalloproteinase-3/genetics , Transcriptional Activation/drug effects , Tumor Cells, Cultured
SELECTION OF CITATIONS
SEARCH DETAIL
...